The results suggested that the dual-targeted PLGA NBs had the stronger targeting ability, which was receptor-mediated through the combination of dual-targeted NBs and both HER2 on the SKBR3 tumor cells and VEGFR2 on the tumor vascular endothelial cells. This evidence concerns the gene ERBB2 and neoplasm.